FDA details scope of cGMP revamp

摘要

FDA says it has completed the first stage of a two-year plan to revamp cGMP rules for drug manufacture.The proposal includes a key industry request that manufacturers be allowed to make certain types of changes to their processes without prior FDA approval,andit also clarifies the scope of FDA's requirements for electronic record keeping and regulatory submissions.